The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology
Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy). New generation of monoclonal antibodies (bi-specific antibodies) are considered active immunotherapies because they link immune cells and cancer cells to activate anti-cancer immune response. Due to their cancer-targeting properties, many different antibody therapies are currently being evaluated and several antibody-based immunotherapies have been approved.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 130+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cancer monoclonal antibody therapy.
Key players in cancer monoclonal antibody therapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to cancer monoclonal antibody therapy
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Immatics||529||Unlock company profile|
|F. Hoffmann-La Roche||520||Unlock company profile|
|Amgen||410||Unlock company profile|
|Johnson & Johnson||266||Unlock company profile|
|AbbVie||231||Unlock company profile|
|Bristol-Myers Squibb||219||Unlock company profile|
|Iovance Biotherapeutics||206||Unlock company profile|
|OncoTherapy Science||203||Unlock company profile|
|Regeneron Pharmaceuticals||144||Unlock company profile|
|Sanofi||142||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||130||Unlock company profile|
|Takeda Pharmaceutical||129||Unlock company profile|
|GSK||124||Unlock company profile|
|UCB||123||Unlock company profile|
|Merck & Co||119||Unlock company profile|
|Kirin Holdings||107||Unlock company profile|
|Eisai||95||Unlock company profile|
|Abbott Laboratories||84||Unlock company profile|
|Gilead Sciences||83||Unlock company profile|
|Daiichi Sankyo||83||Unlock company profile|
|Lundbeck Foundation||81||Unlock company profile|
|E. Merck||73||Unlock company profile|
|AstraZeneca||72||Unlock company profile|
|Esbatech Alcon Biomed Research Unit||62||Unlock company profile|
|Innovative Cellular Therapeutics||61||Unlock company profile|
|Eli Lilly and||60||Unlock company profile|
|XOMA||60||Unlock company profile|
|Grifols||59||Unlock company profile|
|Zoetis||58||Unlock company profile|
|bluebird bio||57||Unlock company profile|
|Autolus||56||Unlock company profile|
|C. H. Boehringer Sohn||55||Unlock company profile|
|Pfizer||55||Unlock company profile|
|UK Research and Innovation||54||Unlock company profile|
|XBiotech||53||Unlock company profile|
|Acorda Therapeutics||50||Unlock company profile|
|Jiangsu Hengrui Medicine||46||Unlock company profile|
|Xencor||45||Unlock company profile|
|Abbott Biotechnology||44||Unlock company profile|
|Miltenyi Biotec||40||Unlock company profile|
|Pierre Fabre Foundation||38||Unlock company profile|
|CRISPR Therapeutics||37||Unlock company profile|
|Biocad||35||Unlock company profile|
|Light Chain Bioscience||35||Unlock company profile|
|Fred Hutchinson Cancer Research Center||34||Unlock company profile|
|Gracell Biotechnologies||31||Unlock company profile|
|Hanmi Science||31||Unlock company profile|
|MacroGenics||28||Unlock company profile|
|Lykera biomed||28||Unlock company profile|
|Vaccinex||28||Unlock company profile|
Source: GlobalData Patent Analytics
Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy. The company is largely involved in immuno-oncology. Immatics undertakes the discovery of targets for cancer immunotherapies with the development of the right T-cell receptors. It has undertaken the development of adoptive cell therapies and TCR bispecifics.
In terms of application diversity, Immatics is the top company, followed by Regeneron Pharmaceuticals and Acorda Therapeutics. By means of geographic reach, Grifols holds the top position, while Acorda Therapeutics and Lykera Biomed are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.